BioSpace News Archive

Transposon Therapeutics announced final results from its Phase 2 study of TPN-101 for the treatment of progressive supranuclear palsy.

Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, hosted members of Congress focused on strengthening the U.S. bioeconomy in service of national and economic security yesterday.

Nicoya®, a pioneering life science instrument company specializing in innovative biosensor technology, is pleased to announce the appointment of Medispec as its exclusive distributor in India.

Onkos Surgical presented Monday, February 12th at the Canaccord Genuity Musculoskeletal Conference in San Francisco.

Accuray Incorporated (NASDAQ: ARAY) announced today that the team at Quebec’s Montérégie Integrated Cancer Center, part of Charles-LeMoyne Hospital, is the first in Canada to treat cancer patients using the company’s Radixact® radiation therapy delivery system.

Candel Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for CAN-3110 -- a first-in-class, replication-competent herpes simplex virus-1 (HSV-1) oncolytic viral immunotherapy candidate.

Areteia Therapeutics Announces Additional $75MM in Series A Financing for Oral Dexpramipexole in Eosinophilic Asthma.

Tonix Pharmaceuticals Holding Corp. today announced that it has engaged Rho, Inc. (Rho), a global contract research organization (CRO), to support Tonix’s preparation and planned submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the management of fibromyalgia.

Nanox announced that its deep-learning medical imaging analytics subsidiary, Nanox AI Ltd., received 510 clearance by the U.S. Food and Drug Administration for HealthFLD, an artificial intelligence software that provides automated qualitative and quantitative analysis of liver attenuation from routine contrast and non-contrast chest and abdomen CT scans in patients between the ages of 18 to 75.

Ace Vision Group, Inc., an emerging medical device company at the forefront of pioneering rejuvenation therapy for the aging eye and presbyopia, announced that it has named Val Kolesnitchenko, MD, as Chief Scientific Officer.